Cargando…
AZGP1 activation by lenvatinib suppresses intrahepatic cholangiocarcinoma epithelial-mesenchymal transition through the TGF-β1/Smad3 pathway
Intrahepatic cholangiocarcinoma (ICC) is a primary liver malignancy and is characterized by highly aggressive and malignant biological behavior. Currently, effective treatment strategies are limited. The effect of lenvatinib on ICC is unknown. In this study, we found that AZGP1 was the key target of...
Autores principales: | Deng, Liming, Bao, Wenming, Zhang, Baofu, Zhang, Sina, Chen, Ziyan, Zhu, Xuewen, He, Bangjie, Wu, Lijun, Chen, Xiaohu, Deng, Tuo, Chen, Bo, Yu, Zhengping, Wang, Yi, Chen, Gang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10480466/ https://www.ncbi.nlm.nih.gov/pubmed/37669935 http://dx.doi.org/10.1038/s41419-023-06092-5 |
Ejemplares similares
-
The prognostic value of sarcopenia combined with preoperative fibrinogen–albumin ratio in patients with intrahepatic cholangiocarcinoma after surgery: A multicenter, prospective study
por: Yu, Haitao, et al.
Publicado: (2021) -
A Novel Clinical-Radiomics Model Based on Sarcopenia and Radiomics for Predicting the Prognosis of Intrahepatic Cholangiocarcinoma After Radical Hepatectomy
por: Deng, Liming, et al.
Publicado: (2021) -
Exploration and validation of a novel ferroptosis-related gene signature predicting the prognosis of intrahepatic cholangiocarcinoma: Ferroptosis-related gene model for ICC
por: Yao, Xinfei, et al.
Publicado: (2022) -
M2 macrophage inhibits the antitumor effects of Lenvatinib on intrahepatic cholangiocarcinoma
por: Yang, Long, et al.
Publicado: (2023) -
Lenvatinib Combined With a PD-1 Inhibitor as Effective Therapy for Advanced Intrahepatic Cholangiocarcinoma
por: Xie, Lulu, et al.
Publicado: (2022)